---
schema_version: "secwatch.filing_event.v1"
accession: "0001079973-23-000728"
form_type: "8-K"
ticker: "CFOR"
cik: "0001293818"
company_name: "CapForce Inc."
filed_at: "2023-05-15T23:59:59+00:00"
generated_at: "2026-06-15T00:45:34.545267+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# OpGen Q1 revenue $0.91M (up 94% YoY), FDA UTI submission, Fisher deal, cash burn guidance

## Summary
- Q1 2023 revenue $0.91M, up 94% YoY ($0.47M) and 26% QoQ ($0.72M).
- Submitted De Novo FDA application for Unyvero UTI panel; FDA confirmed complete review initiated.
- Non-exclusive distribution agreement with Fisher Healthcare for Unyvero A50 platform and tests.
- Cash $7.0M at Mar 31; 2023 guidance: revenue $4-5M, net cash consumption $4.5-5M/quarter.

## SEC filing metadata
- accession: 0001079973-23-000728
- form_type: 8-K
- ticker: CFOR
- cik: 0001293818
- company_name: CapForce Inc.
- filed_at: 2023-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1293818/000107997323000728/0001079973-23-000728-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1293818/000107997323000728/opgen_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001079973-23-000728
- JSON: https://secwatch.observer/filing/0001079973-23-000728.json
- Plain text: https://secwatch.observer/filing/0001079973-23-000728.txt

## Key facts
- Earnings Releases
  CapForce Inc. reported first quarter 2023 results: revenue $0.91 million. Guidance reaffirmed.
  - Period: first quarter 2023
  - Revenue: $0.91 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: Total revenue for the first quarter of 2023 was approximately $0.91 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1293818/000107997323000728/0001079973-23-000728-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.